BLBruce T. Liang

Bruce T. Liang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bruce T. Liang has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Kenneth A. Jacobson

    National Institutes of Health

    6 shared publications
  • Jang Eun Lee

    Department of Medicine, Cardiovascular Division, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA

    2 shared publications
  • Bing Hu

    Department of Medicine, Cardiovascular Division, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA

    1 shared publication
  • Bokoch Gary

    Department of Immunology and Cell Biology Scripps Research Institute La Jolla California 92037 USA

    1 shared publication
  • Charles Dougherty

    Department of Medicine, Cardiovascular Division, and Department of Pharmacology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA

    1 shared publication
  • Douglas Stewart

    Department of Medicine, Cardiovascular Division, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania

    1 shared publication

Latest Publications

  • Open Access

    A novel contractile phenotype with cardiac transgenic expression of the human P2X 4 receptor

    by Bing Hu, Qi-Bing Mei, Xiu-Juan Yao, Emily Smith, William H. Barry, Bruce T. Liang

    The P2X 4 receptor is a newly identified receptor expressed in the heart cell. Its function was elucidated with cardiac transgenic (TG) expression of the receptor by using the myocardium‐specific α‐myosin heavy chain promoter. The presence of the transgene was determined by polymerase chain reaction by using primers specific to the receptor and the vector linker region, by Southern blotting of the genomic DNA, and by immunoblotting and immunohistochemistry of both isolated cardiac myocytes and intact hearts. In intact heart study, the P2X 4 receptor TG mouse exhibited significantly elevated basal cardiac contractility with greater rates of contraction and relaxation, left ventricular developed pressure, and cardiac output compared with nontransgenic (NTG) animals but showed no evidence of hypertrophy or heart failure. The TG heart also showed a greater increase of cardiac contractility in response to the P2X receptor agonist 2‐methylthioATP, consistent with overexpression of a functional P2X 4 receptor with consequent increase in the receptor‐mediated response. In isolated cardiac cell study, the TG heart cell showed a similar level of basal contraction amplitude as the NTG heart cell while exhibiting a threefold greater increase in contractility during stimulation by 2‐methylthioATP. Thus, an increased responsiveness of the overexpressed P2X 4 receptor to endogenous ATP is responsible for the enhanced basal cardiac performance in the intact TG heart. The sustained enhanced contractile function with no associated heart pathology in the P2X 4 receptor TG mouse suggests a novel physiologic role of the P2X 4 receptor, that of stimulating the cardiac contractility.


  • Open Access

    A novel cardioprotective role of RhoA: new signaling mechanism for adenosine

    by Lee Jang Eun, Bokoch Gary, Liang Bruce T.

    Adenosine exerts a potent cardioprotective effect that is mediated by adenosine A 1 and A 3 receptors. The signaling pathways activated by the A 1 and A 3 receptors are distinct and involve selective coupling to phospholipases C and D, respectively. The objective of our study was to elucidate the signaling mechanism that mediates the coupling of each receptor to its respective phospholipase and to test the role of RhoA as a novel mediator leading from adenosine receptors to cardioprotection. C3 transferase and dominant negative RhoA (RhoAT19N) blocked the A 3 receptor‐mediated phospholipase D activation and cardioprotection but had no effect on A 1 receptor‐mediated phospholipase C activation or cardioprotection. In contrast, pertussis toxin treatment caused a greater inhibition of the diacylglycerol accumulation induced by the A 1 agonist than by the A 3 agonist, and it completely abrogated the A 1 agonist‐mediated cardioprotection. Thus, adenosine A 1 and A 3 receptors are linked to different G‐proteins. The A 3 receptor is coupled via RhoA to activate phospholipase D in exerting its car‐dioprotective effect, whereas the A 1 receptor is linked via G i to phospholipase C to produce cardioprotective responses. The present study identifies a novel role for RhoA and further suggests its importance in regulating cardiac cellular function.


  • Adenosine A1 and A3 receptors: Distinct cardioprotection

    by Bruce T. Liang, Douglas Stewart, Kenneth A. Jacobson

    Adenosine is released in large amounts during myocardial ischemia and exerts potent cardioprotective effects in the heart. Although these observations on adenosine have been known for a long time, how adenosine acts to achieve its antiischemic effect remains incompletely understood. Recent advances in the chemistry and pharmacology of adenosine receptor ligands have provided important and novel information on the function of adenosine receptor subtypes in the cardiovascular system. The development of model systems for the cardiac actions of adenosine has yielded important insights into its mechanism of action and have begun to elucidate the sequence of signaling events from receptor activation to the actual exertion of its cardioprotective effect. The goal of the current article is to review recent advances on the cellular and molecular mechanisms that mediate the cardiac actions of adenosine and to show the cardioprotective effect of novel adenosine ligands. Drug Dev. Res. 52:366–378, 2001.


  • Distinct cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D

    by Mollie Parsons, Laura Young, Jang Eun Lee, Kenneth A. Jacobson, Bruce T. Liang

    Adenosine released during cardiac ischemia exerts a marked protective effect in the heart that is mediated by the A1 and A3 subtypes of adenosine receptors. The signaling pathways activated by these adenosine receptors have now been characterized in a chick embryo ventricular myocyte culture model of cardioprotection against ischemia. Selective A1 and A3 receptor agonists were shown to activate phospholipases C and D, respectively, to achieve their distinct cardioprotective effects. The specificity of the A3 receptor–phospholipase D interaction was also demonstrated in chick embryo atrial myocytes (which do not express endogenous A3 receptors) that had been transfected with a vector encoding the human A3 receptor. Activation of both endogenous A1 and A3 receptors in ventricular myocytes resulted in a protective response greater than that induced by stimulation of either receptor alone. Agonists that activate both adenosine A1 and A3 receptors may thus prove beneficial for the treatment of myocardial ischemia.—Parsons, M., Young, L., Lee, J. E., Jacobson, K. A., Liang, B. T. Distinct cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D.


  • Adenosine and Ischemic Preconditioning

    by Bruce T. Liang, Tomasz A. Swierkosz, Howard C. Herrmann, Stephen Kimmel, Kenneth A. Jacobson

    Adenosine is released in large amounts during myocardial ischemia and is capable of exerting potent cardioprotective effects in the heart. Although these observations on adenosine have been known for a long time, how adenosine acts to achieve its anti-ischemic effect remains incompletely understood. However, recent advances on the chemistry and pharmacology of adenosine receptor ligands have provided important and novel information on the function of adenosine receptor subtypes in the cardiovascular system. The development of model systems for the cardiac actions of adenosine has yielded important insights into its mechanism of action and have begun to elucidate the sequence of signalling events from receptor activation to the actual exertion of its cardioprotective effect. The present review will focus on the adenosine receptors that mediate the potent anti-ischemic effect of adenosine, new ligands at the receptors, potential molecular signalling mechanisms downstream of the receptor, mediators for cardioprotection, and possible clinical applications in cardiovascular disorders.


  • Additive Effects of Late Preconditioning Produced By Monophosphoryl Lipid A and the Early Preconditioning Mediated By Adenosine Receptors and K ATP Channel

    by Kristyne Stambaugh, Gary T. Elliott, Kenneth A. Jacobson, Bruce T. Liang

    Background —The cardioprotective effect of preconditioning can be exerted within 1 to 2 hours after initial ischemia, termed classical or early preconditioning, or can reappear 24 hours later as second window or late preconditioning. The objective of this study was to study the interaction between late and early preconditioning and to determine the potential underlying mechanism. Methods and Results —Adenosine receptor agonists and a K ATP channel opener were used to achieve early preconditioning, and Monophosphoryl lipid A (MLA) was used to induce late preconditioning. Cultured chick ventricular myocytes were used as a myocyte model of simulated ischemia and preconditioning. Prior treatment of the myocyte with MLA caused a dose-dependent decrease in the ischemia-induced myocyte injury 24 hours later, consistent with a late preconditioning effect. L-NMMA, glibenclamide, or 5-hydroxydecanoic acid administered during the ischemia blocked the MLA effect. Twenty four hours after MLA treatment, a 5-minute exposure to ischemia, adenosine, adenosine A 1 agonist CCPA, or A 3 agonist resulted in less myocyte injury during the subsequent prolonged ischemia, as compared with cells pretreated with the vehicle and subsequently exposed to the same early preconditioning stimuli. In addition to its ability to enhance the early preconditioning effect by A 1 and A 3 agonists, MLA pretreatment also increased the phorbol ester- and pinacidil-mediated early preconditioning effect. Conclusions —This study defined a novel interaction in which the cardioprotective effect of early preconditioning is additive to that of late preconditioning and raised the possibility that both agents can be used as combined therapy in the treatment of ischemic heart disease.


  • Direct Preconditioning of Cardiac Myocytes via Opioid Receptors and KATPChannels

    by Bruce T. Liang, Garrett J. Gross

    —Previous studies demonstrated that opioid receptor activation mimics the cardioprotective effect of ischemic preconditioning via KATPchannels in the intact heart. However, it is unknown whether this beneficial effect is exerted at the level of the cardiac myocyte or coronary vasculature or is mediated via the sarcolemmal or the mitochondrial KATPchannel. Thus, the purpose of the present study was to investigate whether opioid receptor stimulation could mimic the cardioprotective effect of preconditioning in a cardiac myocyte model of simulated ischemia. Cardiac ventricular myocytes cultured from chick embryos 14 days in ovo were used as an in vitro model for ischemic preconditioning. A 5-minute exposure of the myocytes to the opioid receptor agonist morphine protected the myocytes during a subsequent 90-minute period of simulated ischemia, which was manifested as a pronounced reduction in the percentage of cardiac cells killed and the amount of creatine kinase released during ischemia. The preconditioning-like effect of morphine was concentration-dependent, reached a maximal effect at 1 μmol/L, and was reversed by naloxone (0.1 to 10 μmol/L). When KATPchannel antagonists, such as glibenclamide, or the mitochondrial selective inhibitor 5-hydroxydecanoic acid were present during preexposure to morphine, they abolished the protective effect of morphine. Thus, cardiac myocytes express functional opioid receptors, and their activation mimics the cardioprotective effect of ischemic preconditioning. These results provide direct evidence that the preconditioning-like effect of morphine in the intact heart can be exerted at the level of cardiac myocytes and is most likely the result of mitochondrial KATPchannel activation.


  • Open Access

    Protein kinase C-dependent activation of KATP channel enhances adenosine-induced cardioprotection

    by Bruce T. Liang

    Prior activation of protein kinase C (PKC) can precondition the cardiac cell against injury during subsequent ischaemia. By using cultured chick ventricular cell model for simulated ischaemia and preconditioning, the present study investigated the biochemical mechanism underlying the PKC-mediated preconditioning. A 5 min exposure to PMA enhanced the ability of pinacidil to mediate cardioprotection during a subsequent 90 min period of ischaemia, which is consistent with a sustained activation of the KATP channel initiated by PKC. The brief prior exposure to PMA was also associated with an enhanced ability of the adenosine A1 or A3 receptor agonist 2-chloro-N6-cyclopentyladenosine or N6-(3-iodobenzyl)adenosine-5´-N-methyluronamide to elicit a cardioprotective response during the subsequent ischaemia. In myocytes pretreated with PMA, the cardioprotection mediated by receptor agonist was blocked by the concomitant presence of KATP-channel antagonists glibenclamide or 5-hydroxydecanoic acid during the ischaemia. Thus the KATP channel acts downstream of the adenosine A1 and A3 receptors in mediating the protective effect due to prior PMA exposure. KATP channel activation is responsible for the adenosine receptor-mediated effect. PMA treatment had no effect on other A1 or A3 receptor-mediated effects such as the inhibition of adenylate cyclase, ruling out a direct stimulation of the receptor or G-protein by PMA. The present results indicate that prior stimulation of PKC causes a sustained KATP channel activation, which in turn renders the myocyte more responsive to the protective action of adenosine A1 and A3 receptor agonists during the subsequent ischaemia.


  • Open Access

    Cardiac myocytes rendered ischemia resistant by expressing the human adenosine A1 or A3 receptor

    by Charles Dougherty, Julie Barucha, Peter R. Schofield, Kenneth A. Jacobson, Bruce T. Liang

    Adenosine is an important mediator of the endogenous defense against ischemia‐induced injury in the heart. Adenosine can achieve cardioprotection by mediating the effect of ischemic preconditioning and by protecting against myocyte injury when it is present during the infarct‐producing ischemia. A novel adenosine A3 receptor can mediate this protective function. One approach to achieve cardioprotection is to enhance myocardial sensitivity to the endogenous adenosine by increasing the number of adenosine receptors instead of administering an adenosine receptor agonist. The objective of the present study was to investigate whether genetic manipulation of the cardiac myocyte, achieved by gene transfer and overexpression of the human A3 receptor cDNA, renders the myocytes resistant to the deleterious effect of ischemia. Prolonged hypoxia with glucose deprivation, causing myocyte injury and adenosine release, was used to simulate ischemia in cultured chick embryo ventricular myocytes. During simulated ischemia, cultured myocytes with enhanced expression of the human A3 receptor and showed significantly higher ATP content, fewer cells killed, and less creatine kinase released into the medium than either control or mock‐transfected myocytes. Also, increased expression of the A3 receptor caused an enhanced cardioprotective effect by the preconditioning ischemia. Overexpressing the adenosine A1 receptor also led to increased protection against ischemia‐induced myocyte injury as well as an enhanced preconditioning effect. Thus, increasing the receptor level improves the myocyte sensitivity to the endogenous adenosine, which in turn causes all of the cardioprotective effects found for exogenously administered adenosine agonists. The study provides the first proof for the new concept that an increased expression of the human A3 receptor in the cardiac myocyte can be an important cardioprotective therapeutic approach.—Dougherty, C., Barucha, J., Schofield, P. E., Jacobson, K. A., Liang, B. T. Cardiac myocytes rendered ischemia resistant by expressing the human adenosine A1 or A3 receptor. FASEB J. 12, 1785–1792 (1998)


  • Adenosine receptor subtypes and cardioprotection

    by Jang Eun Lee, Karen Wilcox, Kenneth A. Jacobson, Marc Dichter, Bruce T. Liang

    Brief ischemia prior to a sustained period of ischemia reduces myocardial infarct size, a phenomenon known as preconditioning. A cardiac ventricular myocyte model has been developed to investigate the role and signaling mechanism of adenosine receptor subtypes in cardiac preconditioning. A 5-min exposure of cardiac myocytes to simulated ischemia, termed preconditioning ischemia, prior to a subsequent 90-min period of ischemia protected them against injury incurred during the 90-min ischemia. Preconditioning ischemia preserved ATP content, reduced percentage of cells killed, and decreased release of creatine kinase into the medium. Activation of the adenosine A1 receptor with CCPA or the A3 receptor with IB-MECA can replace preconditioning ischemia and mimic the protective effect of preconditioning ischemia. Blockade of the A1 receptor with its selective antagonist DPCPX or of the A3 receptor with the A3 selective antagonist MRS1191 during the preconditioning ischemia resulted in only a partial attenuation of the subsequent protection. Incubation with both DPCPX and MRS1191 or with the nonselective antagonist 8-SPT during the preconditioning ischemia completely abolished the protective effect of preconditioning ischemia. The KATP channel opener pinacidil caused a large activation of the KATP channel current and was able to precondition the myocyte. The KATP channel antagonist glibenclamide blocked the cardioprotective effect of preconditioning ischemia when it was included during myocyte exposure to the preconditioning ischemia, indicating that KATP channel is a requisite effector in mediating preconditioning. A receptor-mediated stimulation of phospholipase C or phospholipase D, with consequent activation of protein kinase C and KATP channel, appears to be the signaling mechanism linking adenosine A1 and A3 receptors to the induction of preconditioning. A model of how ischemic preconditioning is triggered and mediated is proposed. Evidence is accumulating to support its validity.